Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2016; 37(03): 158-167
DOI: 10.4103/0971-5851.190349
ORIGINAL ARTICLE

Evaluation of myeloid cells (tumor-associated tissue eosinophils and mast cells) infiltration in different grades of oral squamous cell carcinoma

Priyanka Debta
Department of Oral and Maxillofacial Pathology, Institute of Dental Science, SOA University, Bhubaneswar, Odisha, India
,
Fakir Mohan Debta
Department of Oral Medicine and Radiology, S.C.B. Dental College and Hospital, Cuttack, Odisha, India
,
Minal Chaudhary
Department of Oral and Maxillofacial Pathology, SPDC, Sawangi, Wardha, Maharashtra, India
,
Smita Bussari
Department of Oral and Maxillofacial Pathology, Aditya Dental College, Beed, Maharashtra, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Corrected by:

Erratum: Evaluation of myeloid cells (tumor-associated tissue eosinophils and mast cells) infiltration in different grades of oral squamous cell carcinomaIndian J Med Paediatr Oncol 2016; 37(03): 319-319
DOI: 10.4103/0971-5851.195754

Abstract

Background: The multifunctional involvement and infiltration of myeloid cells (tumor-associated tissue eosinophils [TATE] and mast cells) can provide a unique opportunity to define relevant effectors functions that may represent novel, therapeutic options for modulation of tumor onset/growth. Aim: Our study aimed to evaluate infiltration of myeloid cells (TATE and Mast cells) infiltration in different grades (WHO grading) of oral squamous cell carcinoma (OSCC). Materials and Methods: Total 30 cases of OSCC were selected for this study. Hematoxylin and eosin stain and toluidine blue special stain, to evaluate TATE and the mast cells infiltration, were used. Three-year follow-up of OSCC cases was done. Result: Among 30 cases, 63.33% cases of OSCC showed TATE-positive and 36.66% cases showed TATE-negative. Regarding mast cells infiltration, 66.66% OSCC cases showed mast cells positive and 33.33% cases did not show significant mast cells infiltration. We found significant association of TATE and mast cells infiltration in OSCC cases. These myeloid cells infiltration significantly associated with age of patients but did not show any significant association with gender, site, and habit of cases. When we compared these cells infiltration with clinical stages and different histological grades of tumor, we found their infiltration is decreasing, from Stages 1 to Stage 3 of tumor and from well to poorly differentiated carcinoma. We have also found the less infiltration of these myeloid in recurrence cases of OSCC. Conclusion: As the infiltration of TATE and mast cells are correlated, along with evaluation of TATE, we should also evaluate the presence of mast cells infiltration in OSCC. The assessment of myeloid cells could become, in the future, useful for therapeutic approaches in this subset of the patient.

Keywords

Mast cells - oral squamous cell carcinoma - tumor-associated tissue eosinophils - toluidine blue


Publication History

Article published online:
12 July 2021

© 2016. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994;44:7-26.
  • 2 Chang SS. American Joint Committee on Cancer. 6th ed. New York: Springer; 2002.
  • 3 Witz IP, Levy-Nissenbaum O. The tumor microenvironment in the post-PAGET era. Cancer Lett 2006;242:1-10.
  • 4 Graziano DF, Finn OJ. Tumor antigens and tumor antigen discovery. Cancer Treat Res 2005;123:89-111.
  • 5 Stewart S, Edward EM. Immunology, Immunopathology and Immunity. 6th ed. Washington D.C.: ASM; 2001. p. 53-8.
  • 6 Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004;4:941-52.
  • 7 Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM. Wintrobe's Clinical Haematology. 10th ed., Vol. 2. London: Williams & Wilkins; 1999. p. 351-8, 362-72.
  • 8 Miller F, de Harven E, Palade GE. The structure of eosinophil leukocyte granules in rodents and in man. J Cell Biol 1966;31:349-62.
  • 9 Lowe D, Jorizzo J, Hutt MS. Tumour-associated eosinophilia: A review. J Clin Pathol 1981;34:1343-8.
  • 10 Ankle RM, Kale DA, Nayak R. Mast cells are increased in leukoplakia, oral submucous fibrosis, oral lichen planus and oral squamous cell carcinoma. J Oral Maxillofac Pathol 2007;11:18-22.
  • 11 Richard BO, William DJ, Timothy GB. Andrew's Diseases of the Skin: Clinical Dermatology. 9th ed. Philadelphia: WB Saunders; 2000. p. 11-2.
  • 12 Galli SJ. Mast cells and basophils. Curr Opin Hematol 2000;7:32-9.
  • 13 Kitamura Y, Kasugai T, Arizono N, Matsuda H. Development of mast cells and basophils: Processes and regulation mechanisms. Am J Med Sci 1993;306:185-91.
  • 14 Crivellato E, Nico B, Ribatti D. Mast cells and tumour angiogenesis: New insight from experimental carcinogenesis. Cancer Lett 2008;269:1-6.
  • 15 Solomon A, Aloe L, Pe'er J, Frucht-Pery J, Bonini S, Bonini S, et al. Nerve growth factor is preformed in and activates human peripheral blood eosinophils. J Allergy Clin Immunol 1998;102:454-60.
  • 16 Bullock ED, Johnson EM Jr. Nerve growth factor induces the expression of certain cytokine genes and bcl-2 in mast cells. Potential role in survival promotion. J Biol Chem 1996;271:27500-8.
  • 17 Culling CF, Allison RT, Barr WT. Cellular Pathology Technique. 4th ed. London, Butterworth – Heinemann Ltd.; 1985. p. 460-1.
  • 18 Alkhabuli JO. Significance of neo-angiogenesis and immuno-surveillance cells in squamous cell carcinoma of the tongue. Libyan J Med 2007;2:30-9.
  • 19 Debta P, Debta FM, Chaudhary M, Wadhwan V. Evaluation of prognostic significance of immunological cells (tissue eosinophil and mast cell) infiltration in oral squamous cell carcinoma. J Cancer Sci Ther 2011;3:201-4.
  • 20 Debta P, Debta FM, Chaudhary M, Dani A. Evaluation of infiltration of immunological cell (tumour associated tissue eosinophils and mast cells) in oral squamous cell carcinoma by using special stains. Br J Med Res 2012;2:75-85.
  • 21 Bancraft JD, Gamble M. Theory and Practice of Histological Techniques. 4th ed. Germany, Elsevier: Churchill Livingstone; 2002. p. 346-7.
  • 22 Finn OJ. Molecular origins of cancer. Cancer immunology. N Engl J Med 2008;358:2704-15.
  • 23 Lorena SC, Dorta RG, Landman G, Nonogaki S, Oliveira DT. Morphometric analysis of the tumor associated tissue eosinophilia in the oral squamous cell carcinoma using different staining techniques. Histol Histopathol 2003;18:709-13.
  • 24 Falconieri G, Luna MA, Pizzolitto S, DeMaglio G, Angione V, Rocco M. Eosinophil-rich squamous carcinoma of the oral cavity: A study of 13 cases and delineation of a possible new microscopic entity. Ann Diagn Pathol 2008;12:322-7.
  • 25 Alkhabuli JO, High AS. Significance of eosinophil counting in tumor associated tissue eosinophilia (TATE). Oral Oncol 2006;42:849-50.
  • 26 Alrawi SJ, Tan D, Stoler DL, Dayton M, Anderson GR, Mojica P, et al. Tissue eosinophilic infiltration: A useful marker for assessing stromal invasion, survival and locoregional recurrence in head and neck squamous neoplasia. Cancer J 2005;11:217-25.
  • 27 Ercan I, Cakir B, Basak T, Ozdemir T, Sayin I, Turgut S. Prognostic significance of stromal eosinophilic infiltration in cancer of the larynx. Otolaryngol Head Neck Surg 2005;132:869-73.
  • 28 Horiuchi K, Mishima K, Ohsawa M, Sugimura M, Aozasa K. Prognostic factors for well-differentiated squamous cell carcinoma in the oral cavity with emphasis on immunohistochemical evaluation. J Surg Oncol 1993;53:92-6.
  • 29 Igarashi T, Urade M, Sugi M. Oral squamous cell carcinoma with eosinophilic infiltration. Jpn J Oral Surg 1985;31:1564-8.
  • 30 Lowe D, Fletcher CD. Eosinophilia in squamous cell carcinoma of the oral cavity, external genitalia and anus – Clinical correlations. Histopathology 1984;8:627-32.
  • 31 Goldsmith MM, Cresson DH, Askin FB. The prognostic significance of stromal eosinophilia in head and neck cancer. Otolaryngol Head Neck Surg 1987;96:319-24.
  • 32 Goldsmith MM, Belchis DA, Cresson DH, Merritt WD 3rd, Askin FB. The importance of the eosinophil in head and neck cancer. Otolaryngol Head Neck Surg 1992;106:27-33.
  • 33 Gao J, He Y, Wu L. The clinical analysis of eosinophil infiltration in human squamous cell carcinoma of buccal mucosa. Hua Xi Kou Qiang Yi Xue Za Zhi 1997;15:228-9, 232.
  • 34 Dorta RG, Landman G, Kowalski LP, Lauris JR, Latorre MR, Oliveira DT. Tumour-associated tissue eosinophilia as a prognostic factor in oral squamous cell carcinomas. Histopathology 2002;41:152-7.
  • 35 Pretlow TP, Keith EF, Cryar AK, Bartolucci AA, Pitts AM, Pretlow TG 2nd, et al. Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res 1983;43:2997-3000.
  • 36 Lowe DG. Carcinoma of the cervix with massive eosinophilia. Br J Obstet Gynaecol 1988;95:393-401.
  • 37 Thompson AC, Bradley PJ, Griffin NR. Tumor-associated tissue eosinophilia and long-term prognosis for carcinoma of the larynx. Am J Surg 1994;168:469-71.
  • 38 Ohashi Y, Ishibashi S, Suzuki T, Shineha R, Moriya T, Satomi S, et al. Significance of tumor associated tissue eosinophilia and other inflammatory cell infiltrate in early esophageal squamous cell carcinoma. Anticancer Res 2000;20:3025-30.
  • 39 Fujii M, Yamashita T, Ishiguro R, Tashiro M, Kameyama K. Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma. Auris Nasus Larynx 2002;29:175-81.
  • 40 Tanooka H, Kitamura Y, Sado T, Tanaka K, Nagase M, Kondo S. Evidence for involvement of mast cells in tumor suppression in mice. J Natl Cancer Inst 1982;69:1305-9.
  • 41 Sand L, Hilliges M, Larsson PA, Wallstrom M, Hirsch JM. Effects of long-term administration of cancer-promoting substances on oral subepithelial mast cells in the rat. Anticancer Res 2002;22:2623-7.
  • 42 Samoszuk M, Kanakubo E, Chan JK. Degranulating mast cells in fibrotic regions of human tumors and evidence that mast cell heparin interferes with the growth of tumor cells through a mechanism involving fibroblasts. BMC Cancer 2005;5:121.
  • 43 Ch'ng S, Sullivan M, Yuan L, Davis P, Tan ST. Mast cells dysregulate apoptotic and cell cycle genes in mucosal squamous cell carcinoma. Cancer Cell Int 2006;6:28.
  • 44 Sinnamon MJ, Carter KJ, Sims LP, Lafleur B, Fingleton B, Matrisian LM. A protective role of mast cells in intestinal tumorigenesis. Carcinogenesis 2008;29:880-6.
  • 45 Ueda T, Aozasa K, Tsujimoto M, Yoshikawa H, Kato T, Ono K, et al. Prognostic significance of mast cells in soft tissue sarcoma. Cancer 1988;62:2416-9.
  • 46 Sharada P, Girish HC, Umadevi HS, Priya NS. Mast cells in health and disease: A riview. J Indian Acad Oral Med Radiol 2006;18:202-5.
  • 47 Tony B, Stephen B, Neil C, Christopher G. Rook's Textbook of Dermatology. 7th ed. Malden, Man: Blackwell Publication; 2004. p.3.73-3.76
  • 48 Theoharides TC, Conti P. Mast cells: The Jekyll and Hyde of tumor growth. Trends Immunol 2004;25:235-41.
  • 49 Marichal T, Tsai M, Galli SJ. Mast cells: Potential positive and negative roles in tumor biology. Cancer Immunol Res 2013;1:269-79.
  • 50 Michailidou EZ, Markopoulos AK, Antoniades DZ. Mast cells and angiogenesis in oral malignant and premalignant lesions. Open Dent J 2008;2:126-32.
  • 51 Baram D, Vaday GG, Salamon P, Drucker I, Hershkoviz R, Mekori YA. Human mast cells release metalloproteinase-9 on contact with activated T cells: Juxtacrine regulation by TNF-alpha. J Immunol 2001;167:4008-16.
  • 52 Huang C, Sali A, Stevens RL. Regulation and function of mast cell proteases in inflammation. J Clin Immunol 1998;18:169-83.
  • 53 Marshall JS. Mast-cell responses to pathogens. Nat Rev Immunol 2004;4:787-99.
  • 54 Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol 2005;6:135-42.
  • 55 Gurish MF, Austen KF. The diverse roles of mast cells. J Exp Med 2001;194:F1-5.
  • 56 Maurer M, Theoharides T, Granstein RD, Bischoff SC, Bienenstock J, Henz B, et al. What is the physiological function of mast cells? Exp Dermatol 2003;12:886-910.
  • 57 Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: Negative, as well as positive, regulators of immunity. Nat Rev Immunol 2008;8:478-86.
  • 58 Rodewald HR, Feyerabend TB. Widespread immunological functions of mast cells: Fact or fiction? Immunity 2012;37:13-24.
  • 59 Knol EF, Olszewski M. Basophils and mast cells: Underdog in immune regulation? Immunol Lett 2011;138:28-31.
  • 60 Iamaroon A, Pongsiriwet S, Jittidecharaks S, Pattanaporn K, Prapayasatok S, Wanachantararak S. Increase of mast cells and tumor angiogenesis in oral squamous cell carcinoma. J Oral Pathol Med 2003;32:195-9.
  • 61 Tomita M, Matsuzaki Y, Onitsuka T. Effect of mast cells on tumor angiogenesis in lung cancer. Ann Thorac Surg 2000;69:1686-90.
  • 62 Davoine F, Sim A, Tang C, Fisher S, Ethier C, Puttagunta L, et al. Eosinophils in human oral squamous carcinoma; role of prostaglandin D2. J Inflamm (Lond) 2013;10:4.
  • 63 Kubo H, Loegering DA, Adolphson CR, Gleich GJ. Cytotoxic properties of eosinophil granule major basic protein for tumor cells. Int Arch Allergy Immunol 1999;118:426-8.
  • 64 Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P, et al. Eosinophils: Biological properties and role in health and disease. Clin Exp Allergy 2008;38:709-50.
  • 65 Pincus SH, Schooley WR, DiNapoli AM, Broder S. Metabolic heterogeneity of eosinophils from normal and hypereosinophilic patients. Blood 1981;58:1175-81.
  • 66 Manthorpe R, Egeberg J, Hesselvik M, Videbaek A. Unique eosinophil granules in a case of T-cell lymphoma. Scand J Haematol 1977;19:129-44.
  • 67 van Herpen CM, van der Laak JA, de Vries IJ, van Krieken JH, de Wilde PC, Balvers MG, et al. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. Clin Cancer Res 2005;11:1899-909.
  • 68 Dasgupta S, Bhattacharya-Chatterjee M, O'Malley BW Jr., Chatterjee SK. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma. Mol Ther 2006;13:183-93.
  • 69 Agarwal A, Rani M, Saha GK, Valarmathi TM, Bahadur S, Mohanti BK, et al. Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma. Immunol Invest 2003;32:17-30.
  • 70 Cormier SA, Taranova AG, Bedient C, Nguyen T, Protheroe C, Pero R, et al. Pivotal advance: Eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J Leukoc Biol 2006;79:1131-9.
  • 71 Rivoltini L, Viggiano V, Spinazzè S, Santoro A, Colombo MP, Takatsu K, et al. In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5. Int J Cancer 1993;54:8-15.
  • 72 Bossé M, Audette M, Ferland C, Pelletier G, Chu HW, Dakhama A, et al. Gene expression of interleukin-2 in purified human peripheral blood eosinophils. Immunology 1996;87:149-54.
  • 73 Levi-Schaffer F, Barkans J, Newman TM, Ying S, Wakelin M, Hohenstein R, et al. Identification of interleukin-2 in human peripheral blood eosinophils. Immunology 1996;87:155-61.
  • 74 Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74.